NCT04007848View on ClinicalTrials.gov

Cobimetinib for BRAF-wild-type or Mutated Histiocytoses

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

October 5, 2021

Study Completion Date

March 14, 2022

Conditions
Disease or R Group Histiocytoses
Interventions
DRUG

Cobimetinib

Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets

DRUG

Placebo oral tablet

Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets

Trial Locations (1)

75013

Service de Médecine interne - La Pitié Salpêtrière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04007848 - Cobimetinib for BRAF-wild-type or Mutated Histiocytoses | Biotech Hunter | Biotech Hunter